stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) Return on assets
Summit Therapeutics PLC's return on assets over the twelve months to 30 June 2026 was −159.1%, up 22.8 percentage points from fiscal 2025 (−181.9%). Over the past ten years it has ranged from −181.9% (fiscal 2025) to 12.8% (fiscal 2019) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −181.9% | (112.62) |
| FY2024 | −69.3% | 72.51 |
| FY2023 | −141.8% | (121.57) |
| FY2022 | −20.3% | 61.83 |
| FY2021 | −82.1% | (29.06) |
| FY2020 | −53.0% | (19.84) |
| FY2019 | −33.2% | (45.99) |
| FY2019 | 12.8% | 48.52 |
| FY2018 | −35.7% | (19.93) |
| FY2018 | −15.8% | 42.60 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ASND Ascendis Pharma A/S compare | 44.3% |
| HALO Halozyme Therapeutics, Inc. compare | 17.1% |
| TECH Bio-Techne Corp compare | 7.07% |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.76% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.20% |
| KYMR Kymera Therapeutics, Inc. compare | −24.4% |
| PCVX Vaxcyte, Inc. compare | −33.0% |
| BBIO BridgeBio Pharma, Inc. compare | −37.5% |
| SMMT Summit Therapeutics PLC | −159.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement